Cartesian Therapeutics, Inc. (RNAC)
Largest Insider Buys in Sector
RNAC Stock Price History Chart
RNAC Stock Performance
About Cartesian Therapeutics, Inc.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, …
Insider Activity of Cartesian Therapeutics, Inc.
Over the last 12 months, insiders at Cartesian Therapeutics, Inc. have bought $11.86M and sold $4.21M worth of Cartesian Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Cartesian Therapeutics, Inc. have bought $11.86M and sold $4.21M worth of stock each year.
Highest buying activity among insiders over the last 12 months: SPRINGER TIMOTHY A () — $23.54M. BARABE TIMOTHY C (director) — $190,500.
The last purchase of 58,295 shares for transaction amount of $1.06M was made by SPRINGER TIMOTHY A () on 2024‑11‑18.
List of Insider Buy and Sell Transactions, Cartesian Therapeutics, Inc.
| 2024-12-10 | Sale | Chief Technology Officer | 2,901 0.012% | $24.35 | $70,640 | -17.05% | ||
| 2024-12-09 | Sale | Chief Technology Officer | 10,763 0.044% | $25.50 | $274,494 | -22.14% | ||
| 2024-11-21 | Sale | Chief Technology Officer | 32,789 0.1278% | $16.67 | $546,560 | +16.10% | ||
| 2024-11-20 | Sale | Chief Technology Officer | 5,700 0.0227% | $17.29 | $98,570 | +12.28% | ||
| 2024-11-19 | Sale | Chief Technology Officer | 200 0.0009% | $19.50 | $3,900 | -0.94% | ||
| 2024-11-18 | Sale | Chief Technology Officer | 34,400 0.134% | $18.39 | $632,641 | +0.97% | ||
| 2024-11-18 | 58,295 0.2238% | $18.12 | $1.06M | +2.50% | ||||
| 2024-11-15 | Sale | Chief Technology Officer | 22,068 0.088% | $17.20 | $379,497 | +9.32% | ||
| 2024-11-15 | Sale | Chief Scientific Officer | 16,065 0.0635% | $17.06 | $274,093 | +9.32% | ||
| 2024-11-15 | Sale | Chief Medical Officer | 20,000 0.0795% | $17.14 | $342,888 | +9.32% | ||
| 2024-11-15 | 277,246 1.0985% | $17.09 | $4.74M | +9.32% | ||||
| 2024-11-14 | Sale | Chief Technology Officer | 25,900 0.0987% | $16.44 | $425,900 | 0.00% | ||
| 2024-11-14 | Sale | Chief Scientific Officer | 36,050 0.1393% | $16.67 | $600,949 | 0.00% | ||
| 2024-11-14 | Sale | Chief Medical Officer | 35,000 0.1309% | $16.13 | $564,645 | 0.00% | ||
| 2024-11-14 | 96,399 0.3658% | $16.37 | $1.58M | 0.00% | ||||
| 2024-10-04 | 80,301 0.4883% | $22.58 | $1.81M | -15.86% | ||||
| 2024-10-03 | 119,906 0.6423% | $19.89 | $2.38M | -9.31% | ||||
| 2024-10-02 | 5,514 0.0258% | $17.38 | $95,822 | +15.40% | ||||
| 2024-08-12 | director | 7,500 0.0353% | $12.70 | $95,250 | +46.85% | |||
| 2024-08-12 | 8,016 0.0378% | $12.72 | $101,968 | +46.85% |